Navigation Links
New Study Finds Cord Blood-derived Stem Cell Treatments Improve Ataxia Patients' Functionality and Quality of Life
Date:9/6/2011

SHENZHEN, China and SAN DIEGO, Calif., Sept. 6, 2011 /PRNewswire-Asia/ -- The Journal of Translational Medicine reports on a new study in which 30 patients with Hereditary Ataxia showed statistically significant improvements in functionality and quality of life after being treated with a combination of cord blood-derived stem cell treatments and physical therapy.  

The study was conducted at the Nanshan Affiliated Hospital of Guangdong Medical College in China, and included the participation of Beike Biotechnology Company (http://www.beikebiotech.com/), China's leading stem cell research and regenerative medicine company, and the San Diego biotech company Medistem, Inc. (MEDS.PK).   The peer-reviewed article is available at: http://www.translational-medicine.com/content/9/1/65 .

Dr. Shengqin Ye, CEO of Beike Biotechnology commented, "This is the first published study of the effects of adult stem cell treatments on patients with Hereditary Ataxia. The results should be enormously encouraging for those who suffer from this difficult condition.  With the combination of stem cells and physical therapy, study participants showed significant and sustained improvement. We are cautiously optimistic that further study will validate the efficacy and safety conclusions we have drawn from the study data."

Hereditary Ataxia is a neurodegenerative disorder characterized by atrophy of the cerebellum, brain stem, or spinal cord.  Manifestations of the condition include a variety of functional impairments relating to speech, walking, swallowing, and other physical activities.  Currently there is no cure for this condition.

Thomas Ichim, CEO of Medistem (MEDS.PK) stated, "The results of this important new study add to the growing body of published clinical research that suggests the efficacy of adult stem cell therapies, and points to their even greater potential in the future.  This study represents a significant step forward for both the scientific and patient communities, alike."

Over the course of the study, participants received 4-6 stem cell treatments via intravenous injection or by cervical or lumbar puncture, and underwent twice-daily 30-minute physical therapy sessions.  The study concluded, "In addition to the early effect seen in some subjects, the measured symptomatic improvements persisted throughout the period of the study, as noted with the follow-up data from a subset of subjects."  Study authors recommend further double blind placebo controlled studies to validate the efficacy, safety and long-term effects of the treatments.

About Beike Biotechnology Company:Shenzhen Beike Biotechnology Co., Ltd. is China's leading biotechnology company focusing on the production of adult stem cells for use in medical therapies. Headquartered in Shenzhen (near Hong Kong) with a flagship regenerative medicine facility at the China Medical City in Jiangsu province, Beike produces a full line of stem cell products derived from umbilical cord, cord blood and autologous bone marrow.  Currently, the stem cell therapies supported by Beike treat a variety of different medical conditions: ataxia, brain injury, cerebral palsy, lower limb ischemia, lupus, multiple sclerosis, muscular dystrophy, spinal cord injury, and optic nerve pathologies.For more information, please contact:Shenzhen Beike Biotechnology Company, Ltd.T. GutmannShenzhen Hi-Tech Industrial ParkTel:   +86-755-8630-9200Email: info@beikebiotech.com Web:   http://www.beikebiotech.com
'/>"/>

SOURCE Beike Biotechnology Co. Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
2. RAND study finds increase in piracy and terrorism at sea
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
7. RainDance and Scripps to Collaborate on Targeted Sequencing for Wellderly Study
8. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
9. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
10. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
11. Germicidal UVC Lights Improve Clinical Pregnancy Rates for IVF Lab, New Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
Breaking Biology News(10 mins):